Logo image of BHTG

BIOHITECH GLOBAL INC (BHTG) Stock Fundamental Analysis

NASDAQ:BHTG - Nasdaq - Common Stock

0.837  -0.01 (-1.54%)

After market: 0.837 0 (0%)

Fundamental Rating

2

Overall BHTG gets a fundamental rating of 2 out of 10. We evaluated BHTG against 83 industry peers in the Commercial Services & Supplies industry. BHTG has a bad profitability rating. Also its financial health evaluation is rather negative. BHTG is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BHTG has reported negative net income.
BHTG Yearly Net Income VS EBIT VS OCF VS FCFBHTG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 -5M -10M

1.2 Ratios

Industry RankSector Rank
ROA -14.64%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BHTG Yearly ROA, ROE, ROICBHTG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 0 200 -200 400

1.3 Margins

Industry RankSector Rank
OM -54.81%
PM (TTM) -60.71%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BHTG Yearly Profit, Operating, Gross MarginsBHTG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 0 -100 -200 -300 -400

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, BHTG has more shares outstanding
The debt/assets ratio for BHTG is higher compared to a year ago.
BHTG Yearly Shares OutstandingBHTG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 5M 10M 15M 20M
BHTG Yearly Total Debt VS Total AssetsBHTG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 10M 20M 30M 40M 50M

2.2 Solvency

BHTG has an Altman-Z score of -1.97. This is a bad value and indicates that BHTG is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of 5.04 is on the high side and indicates that BHTG has dependencies on debt financing.
Industry RankSector Rank
Debt/Equity 5.04
Debt/FCF N/A
Altman-Z -1.97
ROIC/WACCN/A
WACCN/A
BHTG Yearly LT Debt VS Equity VS FCFBHTG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 10M -10M 20M 30M

2.3 Liquidity

BHTG has a Current Ratio of 0.42. This is a bad value and indicates that BHTG is not financially healthy enough and could expect problems in meeting its short term obligations.
BHTG has a Quick Ratio of 0.42. This is a bad value and indicates that BHTG is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.42
Quick Ratio 0.37
BHTG Yearly Current Assets VS Current LiabilitesBHTG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 5M 10M 15M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 35.59% over the past year.
BHTG shows a strong growth in Revenue. In the last year, the Revenue has grown by 208.64%.
Measured over the past years, BHTG shows a very strong growth in Revenue. The Revenue has been growing by 31.24% on average per year.
EPS 1Y (TTM)35.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)208.64%
Revenue growth 3Y34.44%
Revenue growth 5Y31.24%
Sales Q2Q%511.26%

3.2 Future

Based on estimates for the next years, BHTG will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.11% on average per year.
BHTG is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 53.86% yearly.
EPS Next Y46.66%
EPS Next 2Y24.68%
EPS Next 3Y22.58%
EPS Next 5Y11.11%
Revenue Next Year160.6%
Revenue Next 2Y59.88%
Revenue Next 3Y66.05%
Revenue Next 5Y53.86%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BHTG Yearly Revenue VS EstimatesBHTG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
BHTG Yearly EPS VS EstimatesBHTG Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 -0.1 -0.2 -0.3 -0.4 -0.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BHTG. In the last year negative earnings were reported.
Also next year BHTG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BHTG Price Earnings VS Forward Price EarningsBHTG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -11.32
BHTG Per share dataBHTG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

BHTG's earnings are expected to grow with 22.58% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.68%
EPS Next 3Y22.58%

More info and screens

0

5. Dividend

5.1 Amount

BHTG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOHITECH GLOBAL INC

NASDAQ:BHTG (12/10/2021, 8:56:33 PM)

After market: 0.837 0 (0%)

0.837

-0.01 (-1.54%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCommercial & Professional Services
GICS IndustryCommercial Services & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins Owners18.58%
Ins Owner Change0%
Market Cap23.84M
Analysts82.22
Price Target3.57 (326.52%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.76
P/FCF N/A
P/OCF N/A
P/B 4.17
P/tB N/A
EV/EBITDA -11.32
EPS(TTM)-0.38
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.47
BVpS0.2
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.64%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -54.81%
PM (TTM) -60.71%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 5.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.42
Quick Ratio 0.37
Altman-Z -1.97
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y46.66%
EPS Next 2Y24.68%
EPS Next 3Y22.58%
EPS Next 5Y11.11%
Revenue 1Y (TTM)208.64%
Revenue growth 3Y34.44%
Revenue growth 5Y31.24%
Sales Q2Q%511.26%
Revenue Next Year160.6%
Revenue Next 2Y59.88%
Revenue Next 3Y66.05%
Revenue Next 5Y53.86%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A